Overall verdict
Neutral
4.2/10
1-year performance
+113.14%
Score breakdown
Up 113.1% over 1 year, 85% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Profitability 0.0/10.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product ;
regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments ; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration ; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments ;
non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA ; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries ; and ophthalmic products ; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Stephen Griffin
Founded
1983
Employees
235
Revenue / employee
480 081 USD
Next earnings
November 2, 2026 (estimated)
Institutional holders
- BlackRock, Inc.10.83%
- Caligan Partners LP10.72%
- MORGAN STANLEY4.59%
- ACADIAN ASSET MANAGEMENT LLC4.53%
- VANGUARD CAPITAL MANAGEMENT LLC4.27%
- AQR CAPITAL MANAGEMENT LLC4.18%
- BOOTHBAY FUND MANAGEMENT, LLC3.96%
- RENAISSANCE TECHNOLOGIES LLC3.60%
- DIMENSIONAL FUND ADVISORS LP3.37%
- Other institutions41.36%
- Rest of the register8.58%
131 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
22.88 USD
52-week low
9.01 USD
1-year performance
113.14%
Rising
Year-to-date performance
116.46%
Rising
Drawdown
-8.89%
Mild pullback
Position in the 52-week range
85% of range
Against the world ETF
Over 26 years, from December 2000 to September 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 3.7 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Anika Therapeutics | $251,648 |
| World ETF | $66,618 |
| S&P 500 | $92,038 |
| Risk-free placement | $15,841 |
The risk
- Shaking:the share moves 3.7 times as much as the world ETF.
- Worst fall:-89 % between October 2019 and July 2025. $10,000 placed at the top fell to $1,104. The world ETF, at worst: -53 %. The share has not returned to its high yet.
Anika Therapeutics earned 4 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Anika Therapeutics: $251,648
- World ETF: $66,618
- S&P 500: $92,038
- Risk-free placement: $15,841
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Gross margin 62.2%, the company loses 2.6% of its revenue, ROIC -1.9%, ROE -2.2%.
Net margin
-2.59%
Negative
Sector -224.99%|S&P 13.15%
Gross margin
62.16%
Exceptional
Return on equity (ROE)
-2.19%
Negative
Sector -58.98%|S&P 16.61%
Return on invested capital (ROIC)
-1.88%
Negative
Free cash flow margin (FCF)
0.47%
Low
Margin stability
31.4 pts
Very uneven
Revenue to net income
Growth
5.9/10Revenue up 15.6% over 1 year, -2.9% a year over 5.
Revenue (trailing 12 months)
121M USD
Revenue growth (1y)
15.56%
Hyper-growth
Revenue growth (3y)
-27.79%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
156.10%
Sharply revised up
Valuation
1.9/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E
595.6x
Fair
EV / EBITDA
446.4x
Very expensive
Sector 13.6x|S&P 15.2x
PEG
—
Sector 1.61|S&P 0.90
Market cap
279M USD
Financial strength
10.0/10Cash covers 152.1% of the debt, net debt/EBITDA -111.6x.
Net debt / EBITDA
-111.6x
Net cash
Gearing (net debt / equity)
-9.59%
Net cash
Cash
38.4M USD
Cash / market cap
13.77%
Solid
Cash / total debt
152.13%
Net cash
Net debt
-13.2M USD
Equity
137M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 20.60 USD
- MM2019.99
- MM5020.68
- MM20015.66
- RSI 1454.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+7.56%
200-day average slope, 3 months
+27.28%
50-day average slope, 1 month
+5.73%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.17 % per day
Volatility change
-27.93%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 0.04 (2) | 1.05 (1) | 122 (2) | 20 (1) | 0 (2) |
| 2027 | 0.30 (2) | 0.95 (1) | 128 (2) | 22 (1) | 4 (2) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 1, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | ANIK | 4.2 | 3.7 | 279M USD | Not meaningful (loss) | -2.6 % | 15.6 % | -1.9 % | -111.6x | 0.2 % | 113.1 % | ||
| 7 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 8 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 9 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % |
